Microfluidic system allows for rare single-cell enrichment, analysis and retrieval
Celsee Diagnostics, an innovator of cutting-edge liquid-biopsy products announced today the receipt of another patent for the company’s single-cell capture system. The patent, “Cell Capture System and Method of Use”, applies to the company’s fundamental microfluidic technology for single-cell capture, analysis and retrieval, and was assigned U.S. Patent No. 9513195 B2 by the United States Patent and Trademark Office (USPTO).
The patent covers innovations of Celsee Diagnostics’ microfluidic chip for capturing tens of thousands of cells in a single-cell format, performing biochemical analysis on the cells, and removing select cells from the microfluidic device. The system allows automatic enrichment of rare target cells from a large, heterogenous starting sample, followed by on-chip single-cell characterization, including immunochemistry, DNA FISH, mRNA FISH or live cell staining to provide information on individual cells’ morphology or biomarker content.
The optically-clear plastic substrate of the patented microfluidic chip allows imaging of captured cells using brightfield, phase contrast or fluorescence microscopy. Since captured cells are trapped in their own individual chambers, arranged in a regular array, select cells can then be retrieved from the device using a microcapillary tool. This provides the ability for further downstream processing of the retrieved cell(s), such as sequencing, PCR, or cryopreservation.
“The issuance of this patent validates the technological advancements embodied in our product offerings; in this particular instance the ability to provide an enabling technology for single-cell isolation. Celsee products provide access, efficiency and simplicity, the most desirable attributes related to products for use in single-cell isolation, analysis and retrieval,” said Celsee Diagnostics’ President and Chief Executive Officer Kalyan Handique.
About Celsee Diagnostics
Celsee Diagnostics, a privately-held Michigan-based company, develops automated systems for rare CTC enrichment and single-cell analysis. The company’s precise, accurate, and reliable platform for research and clinical diagnostics development will allow healthcare professionals more time to focus on their patients’ therapeutic treatment and outcomes. The label-free Celsee PREP platforms perform all the required processing steps to isolate and execute downstream single-cell analysis including immunochemistry, DNA FISH and mRNA FISH, while the Celsee ANALYZER scans and analyzes the prepared slide automatically.